Recent progress in TGF-β inhibitors for cancer therapy.

[1]  Liangjing Lu,et al.  Understanding Fibrosis in Systemic Sclerosis: Novel and Emerging Treatment Approaches , 2020, Current Rheumatology Reports.

[2]  S. Jimenez,et al.  Increased expression of the transforming growth factor β-inducible gene HIC-5 in systemic sclerosis skin and fibroblasts: a novel antifibrotic therapeutic target. , 2020, Rheumatology.

[3]  Tingting Li,et al.  Matrix stiffness modulates ILK-mediated YAP activation to control the drug resistance of breast cancer cells. , 2019, Biochimica et biophysica acta. Molecular basis of disease.

[4]  Zhi-Heng He,et al.  Cancer-associated fibroblast regulate proliferation and migration of prostate cancer cells through TGF-β signaling pathway. , 2019, Life sciences.

[5]  T. Hu,et al.  Roles of Myosin-Mediated Membrane Trafficking in TGF-β Signaling , 2019, International journal of molecular sciences.

[6]  Hong Zhang,et al.  Transforming growth factor β signaling pathway: A promising therapeutic target for cancer , 2019, Journal of cellular physiology.

[7]  Eduard Batlle,et al.  Transforming Growth Factor-β Signaling in Immunity and Cancer. , 2019, Immunity.

[8]  A. Ooshima,et al.  Phosphorylation status at Smad3 linker region modulates transforming growth factor‐β‐induced epithelial‐mesenchymal transition and cancer progression , 2019, Cancer science.

[9]  Seong-Jin Kim,et al.  Preclinical Studies and a Phase I Trial of the TGF-β Receptor Inhibitor, Vactosertib (TEW-7197), in Combination with Pomalidomide in Patients with Multiple Myeloma Refractory to Bortezomib or Lenalidomide , 2018, Blood.

[10]  M. Shiao,et al.  Sorafenib suppresses TGF‐&bgr; responses by inducing caveolae/lipid raft‐mediated internalization/degradation of cell‐surface type II TGF‐&bgr; receptors: Implications in development of effective adjunctive therapy for hepatocellular carcinoma , 2018, Biochemical pharmacology.

[11]  Y. Kuo,et al.  Polyprenylated polycyclic acylphloroglucinol: Angiogenesis inhibitor from Garcinia multiflora. , 2018, Bioorganic & medicinal chemistry letters.

[12]  Deng-Chyang Wu,et al.  Pentachloropseudilin Inhibits Transforming Growth Factor‐β (TGF‐β) Activity by Accelerating Cell‐Surface Type II TGF‐β Receptor Turnover in Target Cells , 2018, Chembiochem : a European journal of chemical biology.

[13]  M. Shiao,et al.  Pentabromopseudilin: a myosin V inhibitor suppresses TGF-β activity by recruiting the type II TGF-β receptor to lysosomal degradation , 2018, Journal of enzyme inhibition and medicinal chemistry.

[14]  H. Thieme,et al.  First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery , 2017, PloS one.

[15]  Seong-Jin Kim,et al.  Abstract 2647: TGF-β type I receptor inhibitor (TEW-7197) diminishes myeloma progression by multiple immunomodulatory mechanisms in combination with ixazomib , 2017 .

[16]  Jia-Ming Chang,et al.  7‐Dehydrocholesterol (7‐DHC), But Not Cholesterol, Causes Suppression of Canonical TGF‐β Signaling and Is Likely Involved in the Development of Atherosclerotic Cardiovascular Disease (ASCVD) , 2017, Journal of cellular biochemistry.

[17]  Ajay K. Singh,et al.  A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis , 2017, Kidney international reports.

[18]  Ming-Wei Lin,et al.  Cholest-4-en-3-one attenuates TGF-β responsiveness by inducing TGF-β receptors degradation in Mv1Lu cells and colorectal adenocarcinoma cells , 2017, Journal of receptor and signal transduction research.

[19]  Pei-Yu Chen,et al.  Pentabromophenol suppresses TGF-β signaling by accelerating degradation of type II TGF-β receptors via caveolae-mediated endocytosis , 2017, Scientific Reports.

[20]  Z. Wen,et al.  A Small Dibromotyrosine Derivative Purified From Pseudoceratina Sp. Suppresses TGF‐β Responsiveness by Inhibiting TGF‐β Type I Receptor Serine/Threonine Kinase Activity , 2016, Journal of cellular biochemistry.

[21]  N. Senzer,et al.  Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer. , 2016, Gynecologic oncology.

[22]  A. Brandes,et al.  A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. , 2016, Neuro-oncology.

[23]  C. Hill Transcriptional Control by the SMADs. , 2016, Cold Spring Harbor perspectives in biology.

[24]  F. Huang,et al.  DMSO Enhances TGF‐β Activity by Recruiting the Type II TGF‐β Receptor From Intracellular Vesicles to the Plasma Membrane , 2016, Journal of cellular biochemistry.

[25]  F. Huang,et al.  Ethanol Enhances TGF‐β Activity by Recruiting TGF‐β Receptors From Intracellular Vesicles/Lipid Rafts/Caveolae to Non‐Lipid Raft Microdomains , 2016, Journal of cellular biochemistry.

[26]  C. L. Chen,et al.  Betulinic acid enhances TGF-β signaling by altering TGF-β receptors partitioning between lipid-raft/caveolae and non-caveolae membrane microdomains in mink lung epithelial cells , 2016, Journal of Biomedical Science.

[27]  Katsunori Yoshida,et al.  Reversible Human TGF-β Signal Shifting between Tumor Suppression and Fibro-Carcinogenesis: Implications of Smad Phospho-Isoforms for Hepatic Epithelial-Mesenchymal Transitions , 2016, Journal of clinical medicine.

[28]  B. Hontanilla,et al.  Effect of P144® (Anti-TGF-β) in an “In Vivo” Human Hypertrophic Scar Model in Nude Mice , 2015, PloS one.

[29]  G. Giaccone,et al.  A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. , 2015, European journal of cancer.

[30]  L. Desai,et al.  Reciprocal regulation of TGF-β and reactive oxygen species: A perverse cycle for fibrosis , 2015, Redox biology.

[31]  Ming-Wei Lin,et al.  Euphol from Euphorbia tirucalli Negatively Modulates TGF-β Responsiveness via TGF-β Receptor Segregation inside Membrane Rafts , 2015, PloS one.

[32]  S. Estrem,et al.  Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway , 2015, Drug design, development and therapy.

[33]  P. Papageorgis TGFβ Signaling in Tumor Initiation, Epithelial-to-Mesenchymal Transition, and Metastasis , 2015, Journal of oncology.

[34]  N. Senzer,et al.  Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[35]  Jianlin Ren,et al.  Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression , 2015, BMC Cancer.

[36]  J. Berzofsky,et al.  Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008) , 2015, Cancer Immunology, Immunotherapy.

[37]  M. Farmen,et al.  A phase I dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic cancer , 2014, International journal of oncology.

[38]  Jeong-Seok Nam,et al.  EW-7197, a Novel ALK-5 Kinase Inhibitor, Potently Inhibits Breast to Lung Metastasis , 2014, Molecular Cancer Therapeutics.

[39]  J. Berzofsky,et al.  Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma , 2014, PloS one.

[40]  S. Dooley,et al.  Comparative Analysis of TGF-β/Smad Signaling Dependent Cytostasis in Human Hepatocellular Carcinoma Cell Lines , 2013, PloS one.

[41]  A. Paradiso,et al.  Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II , 2013, PloS one.

[42]  G. Giannelli,et al.  Randomized dose comparison phase II study of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 monohydrate (LY) in patients with advanced hepatocellular carcinoma (HCC). , 2013 .

[43]  Y. Koh,et al.  Combined Treatment with Erlotinib and a Transforming Growth Factor-&bgr; Type I Receptor Inhibitor Effectively Suppresses the Enhanced Motility of Erlotinib-Resistant Non–Small-Cell Lung Cancer Cells , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[44]  R. Akhurst,et al.  Complexities of TGF-β Targeted Cancer Therapy , 2012, International journal of biological sciences.

[45]  Martin A Nowak,et al.  Dynamics of targeted cancer therapy. , 2012, Trends in molecular medicine.

[46]  K. Schlingensiepen,et al.  The antisense oligonucleotide trabedersen (AP 12009) for the targeted inhibition of TGF-β2. , 2011, Current pharmaceutical biotechnology.

[47]  S. Dooley,et al.  TGF-β in progression of liver disease , 2011, Cell and Tissue Research.

[48]  Ute Wirkner,et al.  Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761. , 2011, Neoplasia.

[49]  K. Schlingensiepen,et al.  Transforming growth factor‐beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer , 2011, Cancer science.

[50]  B. Hann,et al.  Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TβRI/II kinase inhibition with LY2109761. , 2011, Cancer research.

[51]  G. Remuzzi,et al.  A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis , 2011, Kidney international.

[52]  N. Senzer,et al.  Phase I Trial of TGF-β2 Antisense GM-CSF Gene-Modified Autologous Tumor Cell (TAG) Vaccine , 2011, Clinical Cancer Research.

[53]  C. Gialeli,et al.  Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting , 2011, The FEBS journal.

[54]  M. Zaaroor,et al.  Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study , 2010, Neuro-oncology.

[55]  K. Hahm,et al.  Connection between inflammation and carcinogenesis in gastrointestinal tract: focus on TGF-beta signaling. , 2010, World journal of gastroenterology.

[56]  S. Demaria,et al.  Abstract 1395: Inhibition of transforming growth factor β (TGFβ) increases the therapeutic benefit of radiotherapy in a murine mammary tumor model , 2010 .

[57]  Mikala Egeblad,et al.  Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling , 2009, Cell.

[58]  J. Soria,et al.  Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  S. Thorgeirsson,et al.  Transforming growth factor‐β gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer , 2008, Hepatology.

[60]  J. Berzofsky,et al.  An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments. , 2008, Cancer research.

[61]  V. Tsutsumi,et al.  Resveratrol prevents fibrosis, NF‐κB activation and TGF‐β increases induced by chronic CCl4 treatment in rats , 2008 .

[62]  K. Iles,et al.  Glutathione suppresses TGF-beta-induced PAI-1 expression by inhibiting p38 and JNK MAPK and the binding of AP-1, SP-1, and Smad to the PAI-1 promoter. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[63]  B. Willis,et al.  TGF-β-induced EMT: mechanisms and implications for fibrotic lung disease , 2007 .

[64]  J. Pichler,et al.  Inhibition of TGF-β2 with AP 12009 in Recurrent Malignant Gliomas: From Preclinical to Phase I/II Studies , 2007 .

[65]  K. Miyazono,et al.  Ki26894, a novel transforming growth factor‐β type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line , 2007, Cancer science.

[66]  L. Wakefield,et al.  Development of oncolytic adenovirus armed with a fusion of soluble transforming growth factor-beta receptor II and human immunoglobulin Fc for breast cancer therapy. , 2006, Human gene therapy.

[67]  N. Senzer,et al.  Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  R. Flavell,et al.  Transforming Growth Factor-β Controls Development, Homeostasis, and Tolerance of T Cells by Regulatory T Cell-Dependent and -Independent Mechanisms , 2006 .

[69]  F. Hoffmann,et al.  Inhibition of transforming growth factor-beta1-induced signaling and epithelial-to-mesenchymal transition by the Smad-binding peptide aptamer Trx-SARA. , 2006, Molecular biology of the cell.

[70]  Ralph Weissleder,et al.  Regulatory T cells reversibly suppress cytotoxic T cell function independent of effector differentiation. , 2006, Immunity.

[71]  J. Huang,et al.  TGF‐β control of cell proliferation , 2005 .

[72]  Jesús Prieto,et al.  Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis. , 2005, The Journal of investigative dermatology.

[73]  F. Hoffmann,et al.  Selective inhibition of TGF-β responsive genes by Smad-interacting peptide aptamers from FoxH1, Lef1 and CBP , 2005, Oncogene.

[74]  Jonathan M. Yingling,et al.  Development of TGF-β signalling inhibitors for cancer therapy , 2004, Nature Reviews Drug Discovery.

[75]  L. Pelkmans,et al.  Not just a sink: endosomes in control of signal transduction. , 2004, Current opinion in cell biology.

[76]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[77]  D. Bigner,et al.  SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. , 2004, Molecular cancer therapeutics.

[78]  A. Roberts,et al.  SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7. , 2004, Molecular pharmacology.

[79]  P. Bates,et al.  Recognition of Phosphorylated-Smad2-Containing Complexes by a Novel Smad Interaction Motif , 2004, Molecular and Cellular Biology.

[80]  Ying E. Zhang,et al.  Smad-dependent and Smad-independent pathways in TGF-β family signalling , 2003, Nature.

[81]  J. Massagué,et al.  Mechanisms of TGF-β Signaling from Cell Membrane to the Nucleus , 2003, Cell.

[82]  P. Ko Ferrigno,et al.  Peptide aptamers: tools for biology and drug discovery. , 2003, Briefings in functional genomics & proteomics.

[83]  C. Arteaga,et al.  Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases , 2002 .

[84]  D. Rockey,et al.  Dose‐dependent inhibition of hepatic fibrosis in mice by a TGF‐β soluble receptor: Implications for antifibrotic therapy , 2002, Hepatology.

[85]  S. Dooley,et al.  Roles of TGF-beta in hepatic fibrosis. , 2002, Frontiers in bioscience : a journal and virtual library.

[86]  R. Derynck,et al.  TGF-β signaling in cancer – a double-edged sword , 2001 .

[87]  Michael Platten,et al.  Glioma Cell Invasion: Regulation of Metalloproteinase Activity by TGF-β , 2001, Journal of Neuro-Oncology.

[88]  J. Massagué,et al.  TGFβ Signaling in Growth Control, Cancer, and Heritable Disorders , 2000, Cell.

[89]  Ester Piek,et al.  Role of Transforming Growth Factor-β Signaling in Cancer , 2000 .

[90]  M. Dembo,et al.  Cell movement is guided by the rigidity of the substrate. , 2000, Biophysical journal.

[91]  J. Massagué,et al.  Transcriptional control by the TGF‐β/Smad signaling system , 2000 .

[92]  B. Janji,et al.  Autocrine TGF‐β‐regulated expression of adhesion receptors and integrin‐linked kinase in HT‐144 melanoma cells correlates with their metastatic phenotype , 1999, International journal of cancer.

[93]  A. Churg,et al.  Mechanisms in the pathogenesis of asbestosis and silicosis. , 1998, American journal of respiratory and critical care medicine.

[94]  Xiao-Fan Wang,et al.  Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[95]  R. Leduc,et al.  Processing of Transforming Growth Factor 1 Precursor by Human Furin Convertase (*) , 1995, The Journal of Biological Chemistry.

[96]  Gregory J. Hannon,et al.  pl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest , 1994, Nature.

[97]  Mahlon D. Johnson,et al.  Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. , 1993, The Journal of clinical investigation.

[98]  J. Massagué,et al.  Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-β receptor system , 1991, Cell.

[99]  F. Pouliot,et al.  TGFβ Signaling in the Tumor Microenvironment. , 2021, Advances in experimental medicine and biology.

[100]  D. Rao,et al.  Three-year Follow up of GMCSF/bi-shRNAfurin DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[101]  S. Bhattacharyya,et al.  Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities , 2012, Nature Reviews Rheumatology.

[102]  D. Rao,et al.  Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[103]  R. Liu,et al.  Oxidative stress and glutathione in TGF-beta-mediated fibrogenesis. , 2010, Free radical biology & medicine.

[104]  Ye-Guang Chen Endocytic regulation of TGF-β signaling , 2009, Cell Research.

[105]  J. Mora,et al.  High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. , 2007, Cancer cell.

[106]  B. Olson,et al.  Inhibition of Transforming Growth Factor (TGF)- 1–Induced Extracellular Matrix with a Novel Inhibitor of the TGF- Type I Receptor Kinase Activity: SB-431542 , 2002 .

[107]  D. Kingsley,et al.  The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms. , 1994, Genes & development.

[108]  J. Krstić,et al.  Review Article Transforming Growth Factor-beta and Matrix Metalloproteinases: Functional Interactions in Tumor Stroma-infiltrating Myeloid Cells , 2022 .